- Home
- GDDY vs JAZZ Comparison
GDDY vs JAZZ Comparison
Compare GDDY & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDDY | JAZZ |
|---|---|---|
| Founded | 1997 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 16.1B |
| IPO Year | 2014 | 2007 |
Fundamental Metrics
Financial Performance| Metric | GDDY | JAZZ |
|---|---|---|
| Price | $112.45 | $243.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 22 |
| Target Price | $117.69 | ★ $296.77 |
| AVG Volume (30 Days) | ★ 1.5M | 745.1K |
| Earning Date | 10-29-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.49 | 0.04 |
| Revenue | N/A | ★ $1,618,693,000.00 |
| Revenue This Year | $6.10 | $12.57 |
| Revenue Next Year | $4.93 | $5.14 |
| P/E Ratio | ★ $20.47 | $6,059.13 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $71.59 | $156.95 |
| 52 Week High | $131.74 | $266.38 |
Technical Indicators
Market Signals| Indicator | GDDY | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 54.17 | 63.09 |
| Support Level | $91.05 | $236.70 |
| Resistance Level | $123.29 | $250.49 |
| Average True Range (ATR) | 4.88 | 7.64 |
| MACD | -0.44 | 4.41 |
| Stochastic Oscillator | 54.20 | 86.68 |
Price Performance
Historical ComparisonAbout GDDY GoDaddy Inc.
GoDaddy is a domain registrar, web hosting provider, and website-building platform. As a domain registrar, GoDaddy earns revenue via primary registrations, aftermarket purchases, and renewals. The firm also offers subscriptions spanning digital marketing and productivity tools, do-it-yourself and AI-powered website and online store building, and point-of-sale and payment facilitation solutions. Customers can also purchase add-ons, such as domain protection services against bad actors and other online risks, as well as web hosting.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.